Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 1051 - 1057 of 1057

17 January 2017

HIV Prevention Market Manager 2-Pager

A two-page overview of the HIV Prevention Market Manager. This document describes its mission and activities. For a more detailed description, click here.

Document
21 October 2016

OPTIONS Review and Documentation of M&E Indicators for Oral PrEP

A summary of current monitoring and evaluation of demonstration projects that are delivering Oral PrEP. This overview includes a list of WHO recommended indicators which are also required for reporting under PEPFAR/OGAC.

Monitoring & Evaluation

Document
23 September 2016

PrEP Monitoring Form for Female and Trans Sex Workers

Evaluates potential introduction of PrEP for female and transgender sex workers at Durbar Mahila Samanwaya Committee, a brothel-based project in Sonagachi, and the Ashodaya Samithi project for street-based sex workers based in Mysore.

Monitoring & Evaluation

Document
6 March 2016

MTN-003B

Archived from the MTN website before it was taken down. Primary Objective Compare changes in Bone Mineral Density (BMD) after one year among VOICE participants receiving oral tenofovir disoproxil fumarate (tenofovir or TDF) and emtricitabine (FTC)/TDF (Truvada) compared with oral placebo Study Summary The BMD Substudy was an observational substudy of VOICE designed to assess…

Research

3 June 2015

MTN-017

Archived from the MTN website before it was taken down. Primary Objectives Compare the safety profiles of Truvada®, daily RG tenofovir 1% gel, and receptive anal intercourse (RAI)-associated RG tenofovir 1% gel Evaluate and compare acceptability of Truvada, daily RG tenofovir 1% gel, and RAI-associated RG tenofovir 1% gel Study Summary MTN-017 was a Phase…

Research

15 February 2015

MTN-003 VOICE

Archived from the MTN website before it was taken down. Primary Objectives Estimate the effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and the effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in preventing HIV infection among women at risk for sexually transmitted infection (STI) Evaluate the…

Research

21 February 2014

MTN-003C

Archived from the MTN website before it was taken down. Primary Objectives Explore socio-cultural and contextual factors that participants identify as influencing product use (and non-use) in VOICE Determine if factors identified by participants as influencing product use (and non-use) are different between those who are randomized to the vaginal product arm vs. oral product…

Research